Given the challenges in treating ICI-resistant lung cancer, this study investigates the synergistic effects of SH003 and DTX in anti-PD1-refractory cancer models by simultaneously targeting STAT3-mediated signaling and enhancing immune cell function in the TME. Here, STAT3 is linked to lung cancer.